You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 63 No. 3, March 1960 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Effect of Disalide on the Intraocular Pressure in Man

S. M. DRANCE, M.B., F.R.C.S. (Eng.); F. Carr, B.Sc., F.B.O.A. (Hons.)

AMA Arch Ophthalmol. 1960;63(3):540-543.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Carbonic anhydrase inhibitors form an accepted form of treatment in the glaucomas. They have been accepted in the treatment of chronic simple glaucoma even on a long-term basis. A number of such agents which are now on the market have been tested as hypotensive agents. Becker (1954) introduced acetazolamide (Diamox) as the first hypotensive agent; Leopold (1958) described the action of dichlorphenamide; Langham (1958) discussed the effect of methazolamide (Neptazane) on the intraocular pressure. Posner (1958) and Drance (1959) discussed the action of ethoxzolamide (Cardrase) on the intraocular pressure in man.

In spite of the availability of carbonic anhydrase inhibitors, the search continues for powerful carbonic anhydrase inhibitors which would require less frequent administration and produce less in the way of side-effects in patients. It is still true that side-effects and intolerance constitute the main reason for cessation of therapy with these agents. The present study was under-taken to evaluate . . . [Full Text PDF of this Article]


Author Affiliations

Saskatoon, Sask., Canada

From the Glaucoma Clinic, University Hospital, University of Saskatchewan.


Footnotes

Submitted for publication Nov. 2, 1959.

Supported by a Federal-Provincial grant No. 607-9-160.

Disalide (5-chloro-2,4-disulphamyltoluene) was kindly supplied by British Drug Houses Ltd. which also supported the study with a grant.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1960 American Medical Association. All Rights Reserved.